Advances in the pharmacotherapy of Alzheimer's disease. | Canada Hyperbarics Skip to main content
Review European archives of psychiatry and clinical neuroscience 1994

Advances in the pharmacotherapy of Alzheimer's disease.

Soares JC, Gershon S — European archives of psychiatry and clinical neuroscience, 1994

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The researchers conducted a literature review on various pharmacological agents proposed for treating Alzheimer's disease.

What They Found

The review found that many drug classes, including psychostimulants, anticoagulants, and vasodilators, lacked conclusive evidence of benefit for Alzheimer's disease. Cholinomimetics showed modest benefits in mild-to-moderate AD patients, while other proposed agents like neurotrophic factors and ACE inhibitors awaited confirmatory trials for more substantial benefits.

Canadian Relevance

This review article has no direct Canadian connection.

Study Limitations

As a review published in 1994, this study's findings do not reflect the significant advancements in Alzheimer's disease pharmacotherapy over the subsequent decades.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Review
Category Neurological
Source Pubmed
PubMed ID 7893772
Year Published 1994
Journal European archives of psychiatry and clinical neuroscience
MeSH Terms Alzheimer Disease; Cognition Disorders; Drug Therapy; Humans

Cite This Study

Share
Discuss with a qualified healthcare professional. Then: Review Coverage Guide View Recognised Conditions

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: April 2, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology